Compare Adaptive Biotechnologies Corp (ADPT) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs T-Mobile Us Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while T-Mobile Us Inc trades at $180.31 (market cap $199.92B). The key difference: T-Mobile Us Inc is far larger — about 60× Adaptive Biotechnologies Corp's market cap, and T-Mobile Us Inc pays a 2.21% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TMUS | |
|---|---|---|
Market Cap | $3.33B | $199.92B |
Sector | Health | Media |
52-Week High | $22.37 | $259.01 |
52-Week Low | $10.24 | $167.65 |
Enterprise Value | $3.19B | $317.61B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
T-Mobile US (TMUS) trades at $184.73, up 4.06% on the day, with a bullish analyst consensus but bearish technical signals. The stock shows strong fundamentals with revenue growth to $88.31B in 2025 and a net income margin of 11.65%, though earnings have been mixed with a recent miss in Q4 2025. Recent news includes leadership changes and speculation about SpaceX's potential interest, while cash flow remains positive but projected to decline in 2026.
Outlook: TMUS offers growth potential with solid profitability and analyst targets near $256, but faces risks from competitive pressures and debt levels. Investment appeal hinges on execution amid sector volatility and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
